Category: Press Releases
March 2, 2021 | Press Releases
Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
NEW HAVEN, Conn., March 02, 2021 – Rallybio, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the details of two previously undisclosed pipeline programs. RLYB212 is a novel monoclonal antibody to human platelet antigen (HPA)-1a in preclinical development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disorder that can cause uncontrolled bleeding in fetuses and newborns. RLYB116 is a small protein inhibitor of complement factor 5 (C5) suitable for subcutaneous administration in preclinical development for the treatment of patients with severe and rare diseases of complement dysregulation. Rallybio plans to submit clinical trial applications for both RLYB212 and RLYB116 in the second half of 2021.
January 21, 2021 | Press Releases
Steven Tuch Joins Rallybio to Lead Corporate Development
NEW HAVEN, CT, January 21, 2021 – Rallybio LLC, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Steven Tuch to lead the Company’s corporate development function. In this role, Mr. Tuch, a seasoned healthcare business professional, will have responsibility for Rallybio’s financing and capital allocation strategies and will also partner with the Business Development team to review and assess opportunities for transformative corporate deals, partnerships, and acquisitions.
November 24, 2020 | Press Releases
Rallybio to Present at the 3rd Annual Evercore ISI HealthCONx Conference
NEW HAVEN, Conn., November 24, 2020 – Rallybio, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Martin Mackay, Chief Executive Officer, Jeff Fryer, Chief Financial Officer and Steve Uden, Chief Operating Officer, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 4:20 p.m. Eastern Time.
November 10, 2020 | Press Releases
Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study
NEW HAVEN, Conn., November 10, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that dosing has commenced in a Phase 1/2 study evaluating RLYB211, a plasma-derived hyperimmune globulin, in healthy male participants. RLYB211 is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disorder that can cause uncontrolled bleeding in fetuses and newborns.
November 5, 2020 | Press Releases
Rallybio to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
NEW HAVEN, Conn., November 5, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Steve Uden, M.D., Co-Founder and Chief Operating Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Tuesday, November 10, 2020 at 5:00 p.m. Eastern Time.
November 2, 2020 | Press Releases
Rallybio Appoints Paula Soteropoulos to Board of Directors
NEW HAVEN, Conn., November 2, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that it has appointed Paula Soteropoulos to its Board of Directors. Ms. Soteropoulos is an accomplished biopharmaceutical industry leader with more than 30 years of rare disease experience in strategic and operational leadership areas including drug development, global commercialization, manufacturing, new company formation and company building.
September 11, 2020 | Press Releases
Rallybio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
NEW HAVEN, Conn., September 11, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Martin Mackay, Co-Founder and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020 at 4:15 p.m. Eastern Time.
September 3, 2020 | Press Releases
Rallybio Appoints Helen M. Boudreau to Board of Directors
NEW HAVEN, Conn., September 3, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that it has appointed Helen M. Boudreau, former Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, to its Board of Directors. Ms. Boudreau will also serve as Chair of the Audit Committee.
June 19, 2020 | Press Releases
Jackie Schumacher Joins Rallybio to Lead Global Regulatory Affairs
NEW HAVEN, Conn., June 19, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Jackie Schumacher to lead Global Regulatory Affairs. In this role, Ms. Schumacher will have responsibility for Rallybio’s global regulatory strategy and operations across the portfolio, including the Company’s lead product candidate, RLYB211, which is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
May 28, 2020 | Press Releases
Rallybio Further Broadens Drug Development Capabilities with Addition of Róisín Armstrong, PhD
NEW HAVEN, Conn., May 28, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Róisín Armstrong, PhD. Dr. Armstrong, a seasoned drug developer, will head the development of the Company’s lead program, RLYB211. RLYB211, a plasma-derived hyperimmune globulin, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.